Skip to Content
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines?
Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder?
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?